Partnership for Acceleration of Innovative Diagnostics for Malaria (PARADIGM)

Related program: Diagnostics

Early and accurate diagnosis of malaria is essential for case management and surveillance. In collaboration with national malaria programs, manufacturers, and global stakeholders, the PATH Partnership for Acceleration of Innovative Diagnostics for Malaria (PARADIGM) project is advancing the availability of sensitive diagnostic tests that address current and evolving needs to diagnose, control, and eliminate malaria.

Schematic of status quo RDTs to next generation RDTs

Schematic of status quo RDTs to next generation RDTs

About the Project

PARADIGM supports manufacturers’ efforts to develop more reliable RDTs that will enable national programs to reach their malaria control and elimination goals. Our work supports product development throughout the product development cycle including identification and assessment of novel biomarkers, research and development (R&D), clinical validation, and market introduction. See PARADIGM project 2-pager for more information.

Lab-to-market pathway

Lab-to-market pathway

Resources

Publications
Performance and usability evaluation of three LDH-based malaria rapid diagnostic tests in Kédougou, Senegal
Estimating malaria antigen dynamics and the time to negativity of next-generation malaria rapid diagnostic tests
Analytical Sensitivity Analysis and Clinical Impact Modeling of Rapigen Rapid Diagnostic Tests for Malaria

Read more of our published work here.

Contact

Contact dxinfo@path.org for more information

Acknowledgement

This project is supported by the Gates Foundation. Their support enables us to strengthen diagnostic innovations and access to improve health outcomes.